Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

Overview

The purpose of this study is to determine if there is a relationship between daily consumption of NRPT, over a six-month (26-week) period, and changes in liver fat accumulation, compared to placebo and change from Baseline in healthy volunteers. In addition, an exploratory assessment of markers of inflammation and liver fat metabolism will be examined.

Full Title of Study: “A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 10, 2020

Interventions

  • Dietary Supplement: Group 1 NRPT
    • Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
  • Dietary Supplement: Group 2 NRPT
    • Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
  • Other: Group 3 Placebo
    • Four placebo capsules will be taken once daily in the morning for 26 weeks.

Arms, Groups and Cohorts

  • Experimental: Group 1: 1X dose of NRPT
    • 250 mg of NR and 50 mg of PT
  • Experimental: Group 2: 2X dose of NRPT
    • 500 mg of NR and 100 mg of PT
  • Placebo Comparator: Group 3: Placebo
    • Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate

Clinical Trial Outcome Measures

Primary Measures

  • Change in Fatty Liver Index
    • Time Frame: 6 months
    • Change from Baseline in Fatty Liver Index (FLI) will be evaluated within each subject and compared between treatment groups. FLI: = (e^0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circumference – 15.745) / (1 + e^0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circumference – 15.745) * 100.
  • Change in Hepatic Fat Fraction
    • Time Frame: 6 months
    • Change from Baseline in mean percent HFF across all nine Couinaud segments will be evaluated within each subject and compared between treatment groups.
  • Change in Insulin Resistance (HOMA-IR)
    • Time Frame: 6 months
    • Change from Baseline in HOMA-IR will be evaluated within each subject and compared between treatment groups. HOMA-IR: = ([glucose x insulin]/450) For this measure, the comparison is between the placebo and the two IP groups at end-of-study
  • Change in liver fat content
    • Time Frame: 6 months
    • To determine if there is a dose effect of NRPT on changes from baseline in liver fat content compared to placebo, as determined by MRI-PDFF.

Secondary Measures

  • Safety: Adverse Events
    • Time Frame: 6 months
    • To determine the safety of NRPT as measured by number of adverse events and serious adverse events.
  • Safety: LFT’s
    • Time Frame: 6 months
    • To determine the safety of NRPT as measured by change in liver function tests (AST U/L, ALT U/L, GGT U/L, Alk Phos U/L) from baseline.

Participating in This Clinical Trial

Inclusion Criteria

1. MRI-PDFF of at least 15%, as measured at Visit 2 (Baseline). 2. Men or women between the ages of 18 and 70 years. 3. BMI between 25.0 and 39.9 kg/m2. 4. Non-smokers (>3 months of non-smoking). 5. If on a statin regimen, history (> 1 month) of stable dose. 6. Able to understand and cooperate with study procedures, and have signed a written informed consent prior to any study procedures. Exclusion Criteria:

1. Diagnosis of NASH (Non-Alcoholic Steatohepatitis). 2. Bilirubin >2x ULN 3. Other causes of liver inflammation including Hepatitis A, B or C, HIV, confirmed or suspected cirrhosis, Wilson's disease, autoimmune hepatitis, hemochromatosis, alcoholic steatohepatitis, pancreatitis, or prescription medications known to cause liver damage, or known to be hepatotoxic. (Evidence of hepatocellular injury or hepatocyte ballooning.) 4. Subjects with a history of bariatric surgery. 5. Significant weight loss (> 5% body weight) or rapid weight loss (> 1.6kg/week), within six (6) months of the Screening Visit. 6. Current or recent (within six (6) months of the Screening Visit) history of significant gastrointestinal, renal, pulmonary, hepatic or biliary disease, endocrine diseases (Type II Diabetes permitted) or other invasive weight loss treatments. 7. Individual taking prescription or over-the-counter medications, including dietary supplements, known to alter lipid metabolism or liver function, within four (4) weeks of randomization. 8. Use of supplements containing pterostilbene, resveratrol, nicotinamide, or niacin, or consumption of red wine (more than 8 oz. per week) or blueberries (more than one serving per week). 9. Pregnant or lactating women or women of childbearing potential who are not using an approved method of contraception. A woman is considered to be of childbearing potential unless she is post-hysterectomy, one or more years postmenopausal, or one or more years following tubal ligation. 10. History of significant cardiovascular or coronary heart disease (CVD or CHD, respectively) as defined as having had a coronary artery bypass procedure, coronary stent or angioplasty, or myocardial infarction in the previous six (6) months. 11. History of cancer, other than non-melanoma skin cancer and basal cell carcinoma, within the previous five years. 12. Poorly controlled or uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg). 13. Recent history of prolonged alcohol (>3 months) use (within past six (6) months) or excessive alcohol use, defined as >14 drinks per week (one drink = 12 oz. beer, 4 oz. wine, 1.5 oz. hard liquor). 14. Exposure to any investigational agent within four (4) weeks or five (5) half-lives, prior to the Screening Visit. 15. Subjects planning to undergo surgery during the study period or up to 1 month after the study 16. Any serious psychiatric disease or disorder, which, in the opinion of the investigator, would preclude the subject from participating in the study. 17. Any known intolerance to the investigational ingredients of this investigational product. 18. Has a condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk during the course of the study, including potentially abnormal lab results, due to a traumatic event.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Elysium Health
  • Collaborator
    • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Oliver Chen, PhD, Principal Investigator, Biofortis Clinical Research, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.